-
公开(公告)号:US08207119B2
公开(公告)日:2012-06-26
申请号:US12559704
申请日:2009-09-15
申请人: Teruo Nishida , Yorihisa Uetake , Hiroaki Iwata
发明人: Teruo Nishida , Yorihisa Uetake , Hiroaki Iwata
IPC分类号: A61K38/00 , A61K43/00 , C07K14/705
CPC分类号: C07K14/78 , A61K9/0048 , A61K38/08
摘要: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.
摘要翻译: 目的是找到纤维连接蛋白的最小活性表达位点,阐明该最小单位与眼科学领域相关的作用,并提供具有该最小单位作为有效成分的眼科学成分。 本发明提供一种眼科学组合物,特别是含有肽PHSRN(SEQ ID NO:1)(Pro-His-Ser-Arg-Asn(SEQ ID NO:1))或Ac-Pro的角膜病症治疗剂 作为其衍生物的-His-Ser-Arg-Asn-NH 2或其作为医药用作有效成分的盐。 优选的剂型是眼用制剂。
-
公开(公告)号:US20100099629A1
公开(公告)日:2010-04-22
申请号:US12559704
申请日:2009-09-15
申请人: Teruo NISHIDA , Yorihisa Uetake , Hiroaki Iwata
发明人: Teruo NISHIDA , Yorihisa Uetake , Hiroaki Iwata
CPC分类号: C07K14/78 , A61K9/0048 , A61K38/08
摘要: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.
摘要翻译: 目的是找到纤维连接蛋白的最小活性表达位点,阐明该最小单位与眼科学领域相关的作用,并提供具有该最小单位作为有效成分的眼科学成分。 本发明提供一种眼科学组合物,特别是含有肽PHSRN(SEQ ID NO:1)(Pro-His-Ser-Arg-Asn(SEQ ID NO:1))或Ac-Pro的角膜病症治疗剂 作为其衍生物的-His-Ser-Arg-Asn-NH 2或其作为医药用作有效成分的盐。 优选的剂型是眼用制剂。
-
公开(公告)号:US09234295B2
公开(公告)日:2016-01-12
申请号:US13637167
申请日:2011-03-23
申请人: Akihiro Sato , Yoshihiro Tsuda , Hiroaki Iwata , Akira Tateno , Hiroki Yoshizawa , Tetsuji Hirato
发明人: Akihiro Sato , Yoshihiro Tsuda , Hiroaki Iwata , Akira Tateno , Hiroki Yoshizawa , Tetsuji Hirato
摘要: The method of forming an oxidation resistant coating layer is for forming an oxidation resistant coating layer containing aluminum on a surface layer of a member (A) formed of metallic material. The method includes a plating treatment step (S1) of plating aluminum on a surface of the member (A) in a solvent, and a heat treatment step (S2) of heat-treating the member (A) whose surface has been plated by the plating treatment step (S1).
摘要翻译: 形成抗氧化涂层的方法是在由金属材料形成的部件(A)的表面层上形成含有铝的抗氧化涂层。 该方法包括在溶剂中在构件(A)的表面上电镀铝的电镀处理工序(S1)和热处理工序(S2),其对表面进行镀覆的构件(A)进行热处理 电镀处理工序(S1)。
-
公开(公告)号:US20130008799A1
公开(公告)日:2013-01-10
申请号:US13637167
申请日:2011-03-23
申请人: Akihiro Sato , Yoshihiro Tsuda , Hiroaki Iwata , Akira Tateno , Hiroki Yoshizawa , Tetsuji Hirato
发明人: Akihiro Sato , Yoshihiro Tsuda , Hiroaki Iwata , Akira Tateno , Hiroki Yoshizawa , Tetsuji Hirato
摘要: The method of forming an oxidation resistant coating layer is for forming an oxidation resistant coating layer containing aluminum on a surface layer of a member (A) formed of metallic material. The method includes a plating treatment step (S1) of plating aluminum on a surface of the member (A) in a solvent, and a heat treatment step (S2) of heat-treating the member (A) whose surface has been plated by the plating treatment step (S1).
摘要翻译: 形成抗氧化涂层的方法是在由金属材料形成的部件(A)的表面层上形成含有铝的抗氧化涂层。 该方法包括在溶剂中在构件(A)的表面上电镀铝的电镀处理工序(S1)和热处理工序(S2),其对表面进行镀覆的构件(A)进行热处理 电镀处理工序(S1)。
-
公开(公告)号:US20060234945A1
公开(公告)日:2006-10-19
申请号:US10540446
申请日:2003-12-24
申请人: Teruo Nishida , Yorihisa Uetake , Hiroaki Iwata
发明人: Teruo Nishida , Yorihisa Uetake , Hiroaki Iwata
IPC分类号: A61K38/08
CPC分类号: C07K14/78 , A61K9/0048 , A61K38/08
摘要: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1)(Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.
摘要翻译: 目的是找到纤维连接蛋白的最小活性表达位点,阐明该最小单位与眼科领域相关的作用,并提供具有该最小单位作为有效成分的眼科学组合物。 本发明提供了一种眼科学组合物,特别是含有肽PHSRN(SEQ ID NO:1)(Pro-His-Ser-Arg-Asn(SEQ ID NO:1))或Ac-Pro的角膜病症治疗剂 作为其药物作为有效成分允许的作为其衍生物的盐酸-His-Ser-Arg-Asn-NH 2或其盐。 优选的剂型是眼用制剂。
-
-
-
-